Japan's AMED names 8 projects for pre-designation orphan review

Japan's Agency for Medical Research and Development (AMED) named 8 projects for a pre-designation review as orphan drug commercialization candidates. These include three candidates from Tokyo-based Nobelpharma: N-acetylneuraminic acid for distal myopathy; NPC-14 (arbekacin sulfate) for Duchenne muscular dystrophy and a malaria vaccine. Candidates from other companies include additional indications of anticoagulant drugs from Tokyo-based Asahi Kasei Pharma; pustular psoriasis therapy from Tokyo-based SBI Biotech; GSK2315698 and GSK2398852 for systemic amyloidosis from GlaxoSmithKline ($GSK); therapeutic radiopharmaceuticals for malignant glioma from Tokyo-based Fujifilm RI Pharma; and achondroplasia therapy using anti-FGF2 aptamers from Tokyo-based Ribomic. AMED website

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.